Stock VXRT VAXART, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Vaxart, Inc.

Equities

VXRT

US92243A2006

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-17 pm EDT 		5-day change 1st Jan Change
0.9588 USD -6.00% Intraday chart for Vaxart, Inc. +36.00% +67.39%
May. 13 Transcript : Vaxart, Inc., Q1 2024 Earnings Call, May 13, 2024
May. 13 Vaxart, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Evolution of the average Target Price on Vaxart, Inc.

Price target over the last 5 years

History of analyst recommendation changes

282eaf2e.hy5i5pSw4oTf2gzU4WpMnf3YWUB0W9Uf4fnavPFacMk.xEwngu3Ym8a7oGO3zC8a6JrtbCw6DJZSi9S57pAjH-TMVgS11-OM5-zrew~6c2f26e93012d171ea81fca1753f53c1

Analyst Recommendations on Vaxart, Inc.

B. Riley Upgrades Vaxart to Buy From Neutral, Lifts PT to $2 From $1.50 MT
Cantor Fitzgerald Adjusts Price Target on Vaxart to $4 From $6, Maintains Overweight Rating MT
B. Riley Lowers Vaxart's PT to $1.50 From $6, Reflecting More Conservative Estimate of Ramp-up of Norovirus; Keeps Neutral Rating MT
Cantor Fitzgerald Adjusts Vaxart's Price Target to $8 From $11, Reiterates Overweight Rating MT
B. Riley Trims Vaxart's Price Target to $6 from $7 to Reflect Modest Increased Long Term Cost of Capital Amid Current Macro Conditions; Keeps Neutral Rating MT
B. Riley Lowers Vaxart's Price Target to $7 from $9 to Reflect Long Term Higher Cost of Capital Amid Current Macro Conditions, Keeps Neutral Rating MT
Jefferies Analyst Starts Vaxart at Buy, Adjusts Price Target to $12 From $13 MT
Cantor Fitzgerald Starts Vaxart at Overweight With $15 Price Target MT
VAXART : B. Riley Downgrades Vaxart to Neutral from Buy, Lowers PT to $9 from $13 on 'Underwhelming' Immunogenicity Dataset, Challenging Near-term Catalyst Setup MT
VAXART : Jefferies Initiates Coverage on Vaxart With Buy Rating, $13 Price Target MT
Vaxart : Shares Jump After Piper Sandler Starts Coverage With Overweight Rating MT
VAXART : Piper Sandler Starts Vaxart at Overweight With $18 Price Target MT
VAXART : B. Riley Lowers Vaxart's Price Target to $13 from $16, Keeps Buy Rating MT
VAXART : B. Riley Adjusts Vaxart PT to $16 From $22, Maintains Buy Rating MT
Vaxart, Inc. Announces its Oral Flu Vaccine Significantly Reduced Rate of Influenza Infection in Phase 2 Challenge Study CI
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.9588 USD
Average target price
5 USD
Spread / Average Target
+421.49%
High Price Target
8 USD
Spread / Highest target
+734.38%
Low Price Target
2 USD
Spread / Lowest Target
+108.59%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Vaxart, Inc.

B. Riley
Cantor Fitzgerald
Jefferies & Co.
Piper Sandler

Ratings for Vaxart, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. VXRT Stock
  4. Consensus Vaxart, Inc.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW